Bayer Raises Combined Peak Sales Forecast for Pharma Portfolio
11 January 2023 - 01:06AM
Dow Jones News
By Giulia Petroni
Bayer AG on Tuesday raised its peak sales forecast for its
pharma portfolio to more than 12 billion euros ($12.8 billion) amid
potential blockbuster drugs tracking ahead of schedule and targeted
investments.
The German pharmaceutical company said that drugs Nubeqa and
Kerendia have registered a strong market uptake and could generate
sales of more than EUR3 billion each. Nubeqa is used for the
treatment of prostate cancer patients while Kerendia targets
cardio-renal disease.
Asundexian, which could potentially serve as a distinct option
for the prevention of thrombosis and ischemic strokes, has
projected peak sales of more than EUR5 billion, according to
Bayer.
"New therapeutic targets and modalities are increasingly
contributing to our early development portfolio and already
representing a large part of our annual R&D resources,
reflecting their importance for our renewed strategy," Christian
Rommel, head of research and development, said. "For 2023, we are
expecting several important development milestones for both our
early and late-stage pipeline that will allow us to further advance
medical innovations."
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
January 10, 2023 08:51 ET (13:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024